A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01292213
First received: February 3, 2011
Last updated: May 2, 2013
Last verified: May 2013

February 3, 2011
May 2, 2013
May 2012
February 2013   (final data collection date for primary outcome measure)
Occurrence of Haemophilus influenzae, in the absence of co-infection with other bacteria, in the lower airways of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01292213 on ClinicalTrials.gov Archive Site
  • Occurrence of Haemophilus influenzae, regardless of co-infection with other bacteria, in the lower airways of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of Streptococcus pneumoniae in the lower airways of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of Haemophilus influenzae in cough swabs and nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of Haemophilus influenzae in the lower airways and/or nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Bacterial load of Haemophilus influenzae in the lower airways and nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of Haemophilus haemolyticus in the lower airways and nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Antimicrobial resistance of Haemophilus influenzae in lower airways [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of viral pathogens in the lower airways and nasopharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of Moraxella catarrhalis in the lower airways of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of other bacterial pathogens in the lower airways of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of Streptococcus pneumoniae in cough swabs and nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of Moraxella catarrhalis in cough swabs and nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of Streptococcus pneumoniae in the lower airways and/or nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of other bacterial pathogens in the lower airways and/or nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Bacterial load of Streptococcus pneumoniae in the lower airways and nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Bacterial load of Moraxella catarrhalis in the lower airways and nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of serotypes of Haemophilus influenzae in the lower airways and nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Occurrence of serotypes of Streptococcus pneumoniae in the lower airways and nasopharynx/ oropharynx of cases and controls [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Antimicrobial resistance of Streptococcus pneumoniae in lower airways [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
  • Antimicrobial resistance of Moraxella catarrhalis in lower airways [ Time Frame: 12-15 months from study initiation ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom
Identification and Characterisation of Bacteria Causing Chronic Cough Among Children in the United Kingdom

The purpose of this study is to investigate the role of Haemophilus influenzae and other bacteria in causing chronic cough, through a direct comparison of chronic cough cases and healthy controls recruited from paediatric respiratory clinics in the United Kingdom.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Cough swab, oropharyngeal swab, nasopharyngeal swabs, blood and bronchoscopy/ bronchoalveolar lavage samples.

Non-Probability Sample

Children aged six to 72 months, residing in the United Kingdom. These children will be classified as cases and controls.

Cases will be children who have had persistent cough for greater than eight weeks and are undergoing general anaesthesia for clinically indicated bronchoscopy/ bronchoalveolar lavage as part of the diagnostic process for chronic cough.

Controls will be children who are undergoing general anaesthesia with endotracheal intubation for elective surgery or endoscopy for non-respiratory-related conditions and had no acute or chronic respiratory symptoms during the four weeks prior to the visit.

Chronic Cough
  • Procedure: Cough swab
    Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
  • Procedure: Oropharyngeal swab
    Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
  • Procedure: Nasopharyngeal swabs
    Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
  • Procedure: Blood sample
    Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
  • Procedure: Bronchoscopy/ bronchoalveolar lavage samples
    Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
  • Other: Data collection
    Questionnaire completion.
  • Cases
    Subjects diagnosed with chronic cough who are undergoing general anaesthesia and bronchoscopy/BAL as part of the diagnostic process for chronic cough.
    Interventions:
    • Procedure: Cough swab
    • Procedure: Oropharyngeal swab
    • Procedure: Nasopharyngeal swabs
    • Procedure: Blood sample
    • Procedure: Bronchoscopy/ bronchoalveolar lavage samples
    • Other: Data collection
  • Controls
    Subjects without respiratory symptoms who are undergoing general anaesthesia for elective surgery or endoscopy of non-respiratory-related conditions.
    Interventions:
    • Procedure: Cough swab
    • Procedure: Oropharyngeal swab
    • Procedure: Nasopharyngeal swabs
    • Procedure: Blood sample
    • Procedure: Bronchoscopy/ bronchoalveolar lavage samples
    • Other: Data collection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
19
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who the investigator believes that parent(s)/ legally acceptable representative can and will comply with the requirements of the protocol.
  • A male or female child between, and including, six to 72 months of age at the time of enrolment.
  • Written informed consent obtained from the parent(s)/ legally acceptable representative of the subject.
  • No antibiotic therapy within four weeks prior to the visit.
  • No cystic fibrosis or known major immunodeficiency such as agammaglobulinaemia, T cell deficiency or Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome.
  • No documented evidence or suspicion of gastroesophageal reflux disease.
  • No evidence of an upper viral respiratory infection four weeks prior to the visit.

In addition, all subjects regarded as 'cases' must satisfy all the following criteria at study entry:

  • Persistent cough greater than eight weeks.
  • No response to five-day prednisolone treatment.
  • Chest X-ray showing no evidence of a lobar pneumonia or gross structural abnormality.

In addition, all subjects regarded as 'controls' must satisfy the following criteria at study entry:

  • No respiratory symptoms four weeks prior to the visit.
  • No documented evidence or suspicion of lung disease upon physical examination.

Exclusion Criteria:

  • Concurrently participating in another study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Use of any investigational or non-registered product within 30 days prior to study procedures, or planned use during the study period.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • Child in care.
Both
6 Months to 72 Months
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01292213
112956
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP